Journals / Journal of Urological Surgery / 2021 / Cilt: 8 - Sayı: 3

Relationship Between Immunohistochemical Expression Level of CD47 and Pathological Disease Stage in Prostate Adenocarcinoma

Pages
179–184
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A significant correlation was found between the disease stage and Gleason score, consistently with the literature.Conclusion: We found that CD47 expression level, which was the main purpose of our study, did not differ between malignant and benignpathologies and was also independent from the stage of malignant pathology.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Prostate cancer is one of the most important health problems that affect men.
📊
Key Findings & Data:Inthis study, we aimed to determine whether the level of CD47 glycoprotein expression would have a significant effect in predicting the pathologicalstage of the disease.Materials and Methods: One hundred-eight patients were included in our study.
💡
Conclusion & Impact:A significant correlation was found between the disease stage and Gleason score, consistently with the literature.Conclusion: We found that CD47 expression level, which was the main purpose of our study, did not differ between malignant and benignpathologies and was also independent from the stage of malignant pathology.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: Prostate cancer is one of the most important health problems that affect men. In our country, it is the second most common cancer andcause of death due to the disease. Most studies conducted to predict the pathological stage of the disease before surgery have been unsuccessful. Inthis study, we aimed to determine whether the level of CD47 glycoprotein expression would have a significant effect in predicting the pathologicalstage of the disease.Materials and Methods: One hundred-eight patients were included in our study. Seventy-two of the patients had previously undergone radicalprostatectomy and were divided into two homogenous groups with 36 patients in each, based on whether they had extraprostatic infiltration. Thecontrol group included 36 patients who had undergone open prostatectomy and had pathologic results that revealed adenomatous hyperplasia.Homogenization was achieved based on the randomization results of the groups. The three groups were compared in terms of immunohistochemicalexpression levels of CD47.Results: According to immunohistochemical analysis, there was no significant difference between the groups in terms of CD47 staining patternscore. A significant correlation was found between the disease stage and Gleason score, consistently with the literature.Conclusion: We found that CD47 expression level, which was the main purpose of our study, did not differ between malignant and benignpathologies and was also independent from the stage of malignant pathology.

🔖

Cite This Article

DOĞAN, S., BAĞRIAÇIK, E., SAKAOĞULLARI, Ş., TAŞTEMUR, S., ODABAŞ, Ö. (2021). Relationship Between Immunohistochemical Expression Level of CD47 and Pathological Disease Stage in Prostate Adenocarcinoma. Journal of Urological Surgery, Cilt: 8 - Sayı: 3, 179–184. https://ajindex.com/articles/347500

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Wein A, Kavoussi L, Partin A, Peters C. Campbell-Walsh Urology, 12th ed. Philadelphia: Elsevier&Saunders; 2020
  2. Stephen B. Willingham, Jens-Peter Volkmer, Andrew J. Gentles, Contributed by Irving L. Weissman, January 22;2012:12-19
  3. Veillette A, Chen J. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy. Trends Immunol 2018;39:173-184
  4. Frazier WA, Isenberg JS, Kaur S, Roberts DD. CD47. UCSD Nature Molecule. doi:10.1038/mp. a002870.01
  5. Logtenberg MEW, Scheeren FA, Schumacher TN. The CD47-SIRPα Immune Checkpoint. Immunity 2020;52:742-752
  6. Tsai RK, Rodriguez PL, Discher DE. Self inhibition of phagocytosis: the affinity of ‘marker of self’ CD47 for SIRPalpha dictates potency of inhibition but only at low expression levels. Blood Cells Mol Dis 2010;45:67-74
  7. Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, Majeti R, Weissman IL. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010;2:63-94
  8. Sarfati M, Fortin G, Raymond M, Susin S. CD47 in the immune response: role of thrombospondin and SIRP-alpha reverse signaling. Curr Drug Targets 2008;9:842-850
  9. Isenberg JS, Shiva S, Gladwin M. Thrombospondin-1-CD47 blockade and exogenous nitrite enhance ischemic tissue survival, blood flow and angiogenesis via coupled NO-cGMP pathway activation. Nitric Oxide 2009;21:52-62
  10. Gao L, Chen K, Gao Q, Wang X, Sun J, Yang YG. CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis. Oncotarget 2017;8:22406-22413
  11. Ramon J, Denis J. Prostate cancer. Berlin: Springer; 2007
  12. Bostwick DG, Cheng L. Neoplasms of the Prostate. In: Bostwick DG, Greg M, Cheng L. Urologic surgical pathology. 4th ed. Edinburgh: Elsevier Mosby; 2019. p. 415-418
  13. Humphrey P. Prostate Pathology. Chicago: ASCP Press; 2003
  14. Yoo C, Oh CY, Cho JS, Song C, Seo SI, Ahn H, Hwang TK, Cheon J, Lee KH, Kwon TG, Jung TY, Chung MK, Lee SE, Lee HM, Lee ES, Choi YD, Chung BH, Kim HJ, Kim WJ, Byun SS, Choi HY. Clinical significance of a large difference (≥ 2 points) between biopsy and post-prostatectomy pathological Gleason scores in patients with prostate cancer. J Korean Med Sci 2011;26:507-512
  15. Murata Y, Saito Y, Kotani T, Matozaki T. CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy. Cancer Sci 2018;109:2349-2357
  16. Weiskopf K. Cancer immunotherap